(Health-NewsWire.Net, August 30, 2018 ) The Global Myelodysplastic Syndrome (MDS) Treatment Market is Valued at 2210 million US$ in 2017 and will reach 5760 million US$ by the end of 2025, growing at a CAGR of 12.7% during 2018-2025.
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.
Access this report at: https://www.themarketreports.com/report/global-myelodysplastic-syndrome-mds-treatment-market-professional-survey-report-2018
Companies profiled in this report are Novartis Ag, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd, Sandoz Inc, Dr Reddys Laboratories Limited, Pharmascience Inc, Accord Healthcare Ltd, Mylan N.V. and more.
Analysis by Product Types, with production, revenue, price, market share and growth rate of each type, can be divided into • Azacitidine • Lenalidomide • Decitabine • Deferasirox
Analysis by Applications, this report focuses on consumption, market share and growth rate of Myelodysplastic Syndrome (MDS) Treatment in each application, can be divided into • Refractory cytopenia with unilineage dysplasia • Refractory anemia with ringed sideroblasts • Others
Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1253970
Table of Contents: 1 Industry Overview of Myelodysplastic Syndrome (MDS) Treatment 2 Manufacturing Cost Structure Analysis of Myelodysplastic Syndrome (MDS) Treatment 3 Technical Data and Manufacturing Plants Analysis of Myelodysplastic Syndrome (MDS) Treatment 4 Global Myelodysplastic Syndrome (MDS) Treatment Overall Market Overview 5 Myelodysplastic Syndrome (MDS) Treatment Regional Market Analysis 6 Global 2013-2018E Myelodysplastic Syndrome (MDS) Treatment Segment Market Analysis (by Type) 7 Global 2013-2018E Myelodysplastic Syndrome (MDS) Treatment Segment Market Analysis (by Application) 8 Major Manufacturers Analysis of Myelodysplastic Syndrome (MDS) Treatment 9 Development Trend of Analysis of Myelodysplastic Syndrome (MDS) Treatment Market 10 Myelodysplastic Syndrome (MDS) Treatment Marketing Type Analysis 11 Consumers Analysis of Myelodysplastic Syndrome (MDS) Treatment 12 Conclusion of the Global Myelodysplastic Syndrome (MDS) Treatment Market Professional Survey Report 2017
Inquire more about this report at: https://www.themarketreports.com/report/ask-your-query/1253970
The Market Reports We aim to provide the best industry and market research report to a seeker. Today, ‘The Market Reports’ is a one stop destination for all the report buyers. We have a collection of over 700,000+ research, company, market, SWOT, trends and analysis reports of various countries, categories and domain to meet an organization need. Website: https://www.themarketreports.com/ Write us at sales@themarketreports.com
The Market Reports
Shirish Gupta
+16314071315
web@themarketreports.com
Source: EmailWire.Com
|